BioreclamationIVT said today it has acquired TransCell Science for an undisclosed price in a deal designed to broaden the buyer’ t expertise and offerings in cell culture and cell-based assays.
TransCell is a CRO specializing in the use of primary tissue for phenotypic screening assays. The company says it offers knowledge in cell assays, primary cells, stem cells, plus cell analysis.
According to its website, TransCell’ s customers include “ top 10 pharmaceutical and biotech companies, international personal care products and cosmetics brands, leading academic organizations, and the National Institutes of Health. ”
BioreclamationIVT focuses on control and disease-state matrices manufactured from human and pet biological specimens, and has recently expanded its offerings to incorporate cell processing and phenotypic screening services. The company has been established in 1990 and is based in Westbury, NY.
BioreclamationIVT and TransCell are both privately held.
“ Building upon our own collective synergies, this transaction positions…